ClinicalTrials.gg
TerminatedNCT03996135CIRRVVUSUpdated Nov 12, 2026

Evaluation of Accuvein in Cirrhotics Patients

An interventional study of Cannulation with AccuVein AV400 in Liver Cirrhosis, sponsored by University Hospital, Caen. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University Hospital, Caen · Not applicable, Interventional, and Supportive care

How we know

Why this study was terminated
availability of the principal investigator
Updated Nov 12, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 95 studies in Liver Cirrhosis with a site in France — 22 open to participants now, 25 under way, 2 of them phase 3. Liver Cirrhosis · France.

Enrollment
43rd of 53
85 · median 205
Started
2020
with 3 others
No phase
29 of 95
6 open now
Registered
48th of 95
by date

Among the 95 studies in Liver Cirrhosis with a site in France, this one is the 43rd largest by enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2020, is one of 29 with no phase, and was the 48th registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

22 of the 95 studies in Liver Cirrhosis with a site in France are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Liver Cirrhosis with a site in France, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the effectiveness of AccuVein AV400 to facilitate placement of peripheral intravenous catheters in cirrhotic adults by comparing the success rate of the first attempt to install a peripheral venous catheter with or without AccuVein AV400®.

03

Conditions studied

  • Liver Cirrhosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient older than 18 years old
  • Patient presenting a liver cirrhosis
  • Patient requiring the placement of a venous peripheral catheter
  • Patient informed and giving free and
  • Patient affiliated to a French social security scheme

Exclusion criteria

Exclusion Criteria:

  • Patient under 18 years old
  • Patient unable to give consent
  • Patient under guardianship or curatorship
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Experimental : Cannulation with AccuVein AV400

    Cirrhotic patients benefit from the support of a venous illumination device for each peripheral venous cannulation

    Device: Cannulation with AccuVein AV400

  • No intervention
    Control

    Cirrhotic patients benefit from the standard technique of peripheral veinous catheter placement.

Interventions

  • DeviceCannulation with AccuVein AV400

    Cannulation using AccuVein AV400 device

    Also known as: AccuVein AV400

06

What researchers measure

Primary outcomes

  1. First Attempt Success Rate of Cannulation

    Firt attempt success of positional for each peripheral venous catheter and expressed as a percentage in cirrhotic patients during hospitalization.

    Time frame: baseline

Secondary outcomes

  1. change of the score A-DIVA

    Scores A-DIVA between beginning and end of hospitalization between the two groups

    Time frame: baseline and end of hospitalization (up to a month)

  2. Cost

    Cost of consumables used in euro between the two groups

    Time frame: baseline

  3. Life expectancy of the catheter

    Life expectancy of the catheter between the two groups

    Time frame: baseline

  4. Utilisation of a central venous catheter

    Use of a central venous catheter (y/n)

    Time frame: baseline

  5. Pain's score

    visual analogic scale

    Time frame: baseline

  6. Numbers of attempts

    Number of attempts between two groups

    Time frame: baseline

07

Study locations

1 site
  • Caen University Hospital
    Caen, 14033, France
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2020 to primary completion in Feb 2025, 55 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jun 2023 → Feb 2025 and completion Jun 2023 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2019
First posted
Jun 24, 2019
StartActual
Jun 15, 2020
Primary completionActual
Feb 11, 2025was Jun 2023
CompletionActual
Dec 1, 2025was Jun 2023
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Terminated availability of the principal investigator
changed Nov 12, 2026
Primary completion
Jun 30, 2023→Feb 11, 2025 (actual)
Nov 12, 2026
Study completion
Jun 30, 2023→Dec 1, 2025 (actual)
Nov 12, 2026
Enrollment
280 (estimated)→85 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Status unknown→Terminated
    Why stopped availability of the principal investigator
    Primary completion Jun 30, 2023→Feb 11, 2025 (now actual)
    Study completion Jun 30, 2023→Dec 1, 2025 (now actual)
    Enrollment 280 (estimated)→85 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03996135
Responsible party
Sponsor
First posted
Jun 24, 2019
Start date
Jun 15, 2020
Primary completion
Feb 11, 2025
Completion
Dec 1, 2025
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion